Claim
Strong Support
quantitative

A drug called evolocumab blocks PCSK9 and can lower bad cholesterol by over 80% when added to statins.

63
Pro
0
Against

Evidence from Studies

Supporting (1)

63

Community contributions welcome

63

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

Randomized Controlled Trial
Human
2012 Nov 6
Direct test
Why it supports

The study tested evolocumab (called AMG 145 in the study), which is a drug that helps lower bad cholesterol, and found it reduced LDL cholesterol by up to 81% in people already taking statins, just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Score Breakdown

No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.

Limits worth knowing
  • No clinical evidence is available; the score reflects mechanistic plausibility only.

Sign up to see full verdict

Related Content

Videos (1)

The 60-Year Cholesterol War Is Finally Over

Dr Brad Stanfield

The 60-Year Cholesterol War Is Finally Over

Read analysis